secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2022-04-04T23:59:59+00:00
Accession:  0001140361-22-012901
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences to acquire AltheaDx for $65M upfront plus up to $75M in milestones
--------------------------------------------------------------------------------

- Upfront consideration: $32.5M cash + $32.5M stock; milestone payments up to $75M tied to 2022-2024 revenue and Medicare coverage.
- AltheaDx had <$1M revenue in 2021; its IDgenetix test focuses on mental health pharmacogenomics.
- Expected Q2 2022 close; subject to AltheaDx stockholder approval and other customary conditions.
- CEO Derek Maetzold and Chairman Daniel Bradbury are AltheaDx directors and beneficial owners, creating related-party transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000114036122012901/0001140361-22-012901-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000114036122012901/ny20003735x1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-012901

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer